Johnson & Johnson: New Indications for Anliwei and Zhaokesu Included in the 2026 National Medical Insurance Catalog

On November 14, Johnson & Johnson Innovative Medicine announced that two of its innovative treatment regimens have been successfully included in the 2026 National Reimbursement Drug List (NRDL). Among them, Amvuttra? was included for the first time, and Darzalex Faspro had one additional indication included, covering major disease areas such as generalized myasthenia gravis and multiple myeloma.